Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06366750 · ClinicalTrials.gov registry record · Phase 2
A Study of Barzolvolimab in Patients With Prurigo Nodularis
A Phase 2 study of Prurigo Nodularis, sponsored by Celldex Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT06366750: Active Phase 2 study of Prurigo Nodularis, sponsored by Celldex Therapeutics.
NCT06366750 is a Phase 2 study of Prurigo Nodularis that is active but no longer recruiting, run by Celldex Therapeutics. The registered enrollment target is 140 participants, below the 219-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06366750, a Phase 2 study of Prurigo Nodularis, is active but no longer recruiting, sponsored by Celldex Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with prurigo nodularis.
Primary Outcome
WI-NRS is a validated measure of itch severity. Participants are asked daily to rate the intensity of their worst pruritis (itch) over the past 24 hours using an 11-point scale ranging from 0= no itch to 10= worst imaginable itch. Higher scores indicate more severity.
Conditions Studied
Interventions
- OTHER Matching Placebo
- BIOLOGICAL barzolvolimab
Study Locations (20)
California
- Center for Dermatology Clinical Research, Inc - Fremont
- Profound Research LLC - Oceanside
- Empire Clinical Research - Pomona
- University of California San Francisco - San Francisco
- University of California, San Francisco - San Francisco
- Dermatology Institute & Skin Care Center - Santa Monica
- Focus Clinical Research - West Hills
Florida
- Encore Medical Research Boynton Beach - Boynton Beach
- Biobrilliance Medical Research Center - Hialeah
- Encore Medical Research - Hollywood
- Life Arc Research Centers Corp - Miami
- University of Miami - Miami
- Advanced Clinical Research Institute - Tampa
- Encore Medical Research of Weston - Weston
Alabama
- Total Dermatology - Birmingham
- Cahaba Dermatology Skin Health Center - Birmingham
Arizona
- Investigate MD, LLC - Scottsdale
- Scottsdale Clinical Trials - Scottsdale
Georgia
- Emory University - Atlanta
- Centricity Research - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2024-04-12 |
| Est. Completion | 2027-03 |
| Phase | Phase 2 |
What the registry record for NCT06366750 still lists
NCT06366750 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 219-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (36% lower).
The record links to 1 condition, with Prurigo Nodularis appearing as the primary indexed condition, and to 2 interventions - of which Matching Placebo is the first listed.
NCT06366750 names 20 study sites across 5 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06366750 about?
NCT06366750 is a clinical study titled "A Study of Barzolvolimab in Patients With Prurigo Nodularis". The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with prurigo nodularis.
What is the current status of trial NCT06366750?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2024-04-12. Estimated completion is 2027-03.
What conditions does trial NCT06366750 study?
This clinical trial studies the following conditions: Prurigo Nodularis.
What interventions are being tested in trial NCT06366750?
The interventions under investigation include: Matching Placebo (OTHER), barzolvolimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06366750?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06366750 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prurigo Nodularis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06366750's enrollment target sits among peer trials
140 9th of 14 higher than 6 of 14 other Prurigo Nodularis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prurigo Nodularis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy of CC-10004 for Prurigo Nodularis
COMPLETED · Phase 2
-
Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
COMPLETED · Phase 2
-
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
COMPLETED · Phase 2
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
RECRUITING · Phase 3
-
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
RECRUITING · Phase 3
-
Upadacitinib for Prurigo Nodularis
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI